Having trouble viewing this email? View the online version.
ISSM logo

Latest News from the ISSM - January 3, 2014 Member Login
Testosterone Therapy May Increase Risk of Adverse Outcomes in Some Men

Men with "significant medical comorbidities" may be at higher risk of death, heart attack, and stroke if they undergo testosterone therapy, American researchers report.

Their study, published in November in the Journal of the American Medical Association (JAMA) involved over 8,700 men who had a coronary angiography between 2005 and 2011. At the time of the angiography, all of the men had testosterone levels below 300 ng/dL. 

About 20% of the men had had a previous heart attack, half had diabetes, and over 80% had coronary artery disease.

Fourteen percent of the men started subsequent testosterone therapy, administered by gel, patch, or injection.  The remaining men had no testosterone therapy.

At follow up, the researchers found that death, heart attacks, and strokes were more common among men who had taken testosterone.

According to a press-release from JAMA, "The researchers found that the proportion of patients experiencing events 3 years after coronary angiography was 19.9 percent in the no testosterone therapy group (average age, 64 years) and 25.7 percent in the testosterone therapy group (average age, 61 years), for an absolute risk difference of 5.8 percent.”

To learn more about this study, please click here

New Research: Responders to PDE5 Inhibitors Therapy

A new research summary has been posted to the ISSM website.  

"Nonresponders, Partial Responders, and Complete Responders to PDE5 Inhibitors Therapy According to IIEF Criteria: Validation of an Anchor-Based Treatment Responder Classification" by May Yang, MPH; Xiao Ni, PhD; Angelina Sontag, PhD; Heather J. Litman, PhD; and Raymond C. Rosen, PhD was published in the Journal of Sexual Medicine in October. 

The study addresses the need for clear, standardized definitions that can be used to describe men's response to erectile dysfunction treatment with PDE5 inhibitors. It also discusses ways that clinicians and researchers can use these definitions.

For more details, please click here

2014 Membership Renewal

We would like to again thank you for your continued support and loyalty to the International Society for Sexual Medicine. It is you, the membership community, who drives and shapes the ISSM.

In order to ensure that you will have uninterrupted access to all of ISSM's membership benefits, including the Journal of Sexual Medicine, we kindly ask you to pay your ISSM membership dues for 2014 in a timely manner either through one of our affiliated societies or directly with us through this link. Of course, if you have already paid your membership dues, we thank you.

Also, if your contact information has changed, please take a moment to update it through Your ISSM Membership.

You are receiving this newsletter because you are subscribed to our mailing list.
If you would rather not receive emails like this in the future you can unsubscribe.

ISSM | International Society for Sexual Medicine
P.O. Box 94 | 1520 AB Wormerveer | The Netherlands